Biotricity Stock Story

BTCY -  USA Stock  

USD 4.14  0.09  2.22%

It appears Biotricity will continue to recover much faster as its share price surged up 21.84% today. Biotricity current daily volatility is 5.47 percent, with a beta of 0.77 and an alpha of -0.04 over DOW. While some millenniums are indifferent towards medical equipment, it makes sense to break down Biotricity. Why are we still confident in our projection for a recovery.
Published over a month ago
View all stories for Biotricity | View All Stories
Should you keep an eye on Biotricity (NASDAQ:BTCY) management before November?
Biotricity currently holds roughly 614.47 K in cash with (11.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biotricity has an asset utilization ratio of 42727.27 percent. This suggests that the company is making $427.27 for each dollar of assets. An increasing asset utilization means that Biotricity is more efficient with each dollar of assets it utilizes for everyday operations.
Investing in Biotricity, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Biotricity along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Biotricity's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Biotricity in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Biotricity. Your research has to be compared to or analyzed against Biotricity's peers to derive any actionable benefits. When done correctly, Biotricity's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Biotricity.

How important is Biotricity's Liquidity

Biotricity financial leverage refers to using borrowed capital as a funding source to finance Biotricity ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Biotricity financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Biotricity's total debt and its cash.

How Biotricity utilizes its cash?

To perform a cash flow analysis of Biotricity, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Biotricity is receiving and how much cash it distributes out in a given period. The Biotricity cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Biotricity Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Biotricity reported Net Cash Flow from Operations of (11.08 Million) in 2020

Biotricity Correlation with Peers

Investors in Biotricity can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Biotricity. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Biotricity and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Biotricity is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage.
Please check volatility of Biotricity for more details

Sale by David Rosa of 3318 shares of Biotricity

Legal trades by Biotricity insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biotricity insider trading alert for sale of common stock by David Rosa, the corporate stakeholder, on 13th of October 2021. This event was filed by Biotricity Inc with SEC on 2021-10-13. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Biotricity valued reasonably by the market?

Biotricity appears to be relatively risky, given 3 months investment horizon. Biotricity secures Sharpe Ratio (or Efficiency) of 0.0735, which signifies that the company had 0.0735% of return per unit of risk over the last 3 months. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock-specific technical indicators that cannot be diversified away. We have found twenty-seven technical indicators for Biotricity, which you can use to evaluate the future volatility of the firm. Please makes use of Biotricity's risk adjusted performance of 0.0072, and Mean Deviation of 3.17 to double-check if our risk estimates are consistent with your expectations.

Are Biotricity technical ratios showing a recoup?

Current potential upside is at 5.57. Biotricity exhibits very low volatility with skewness of -0.83 and kurtosis of 4.26. However, we advise investors to further study Biotricity technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biotricity's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biotricity's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Takeaway on Biotricity Investment

While many other companies under the medical devices industry are still a bit expensive, Biotricity may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biotricity.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Biotricity. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com